Doctor Demands Answers from DEA on Psilocybin Rescheduling for Palliative Care

A doctor and his legal team are turning up the heat on the DEA, demanding an update on the status of psilocybin rescheduling. Dr. Sunil Aggarwal has been fighting for years to move "magic mushrooms" from Schedule I to Schedule II, which would finally allow terminally ill patients to access the therapy under Right to Try laws. While the DEA previously signaled they would start a federal review with health officials, they’ve been notoriously quiet since.

Advocates argue that the science is already there, especially with the FDA previously labeling psilocybin a breakthrough therapy. This legal push is a major deal for the community because it challenges the federal government's rigid stance on plant medicine. If successful, it could bridge the gap between experimental research and actual patient access, potentially setting a massive precedent for how we handle other scheduled substances. For everyday enthusiasts, it’s another sign that the walls around traditional prohibition are crumbling, favoring compassionate care and personal liberty over outdated bureaucracy.